Alston & Bird is committed to supporting the life sciences industry’s phenomenal growth and to ensuring that leading scientific research is rapidly translated into real-world innovation and commercialization. As a firm, we have assembled a team with legal talent and scientific proficiency to address our clients’ legal needs, whether those needs relate to intellectual property procurement and enforcement, regulatory compliance, import-export issues, trade regulation, products liability and commercial litigation, public or private equity and debt financing, mergers and acquisitions, strategic alliances or other transactional matters. We possess the necessary legal skills, coupled with an understanding of the life sciences industry, to provide comprehensive legal services, solid business counseling and creative strategic thinking. We understand how the multidisciplinary aspects of the law and science must fit together.
Our client base extends across the United States to Europe, South America and Asia and includes emerging and established biotechnology companies, pharmaceutical and drug delivery companies, nationally acclaimed research centers and universities, health services organizations, medical device companies, investment banking and private equity and venture capital firms targeting life science companies.
Life Sciences
Experience
Where Law and Science Connect ®
The diversity in our experience and technical training in areas of critical importance to life sciences companies distinguishes Alston & Bird from other law firms. Our life sciences practice includes members who collectively hold more than 30 life sciences degrees in all major fields of biology as well as in chemistry, chemical engineering and biomedical engineering, 13 of which are doctorates. We bring a depth of knowledge and expertise in a variety of fields, including pharmacology, biotechnology, genomics, proteomics, therapeutics and drug delivery, medical devices and nanotechnology, and in other chemical, agricultural and health care science areas. Our life sciences clients range from some of the largest biotechnology and pharmaceutical companies in the world to cutting-edge startup companies and also include major medical device companies and world-class research universities.
Accolades
Our life sciences team members include a former U.S. Representative in the House of Representatives; a former senior policy advisor for CMS; a former FDA associate commissioner for legislative affairs; former associate chief counsel at FDA; and a former health policy advisor and counsel to the U.S. Senate Committee on Finance. Our team also includes a former associate general counsel for the American Red Cross, and a board member of the Southeast BIO Organization.
Bringing Value to Our Clients
The life sciences industry continues to expand exponentially. As science and technology becomes more sophisticated and complex, so do the legal challenges faced by the industry. Alston & Bird is prepared to be the law firm of choice to life sciences industry companies. Alston & Bird is Where Law and Science Connect.®
-
Speaking Engagement April 30, 2025Diagnosing the Disease: Regulation of LDTs and IVDsBen Wolf will present during this virtual program hosted by the Practicing Law Institute (PLI).Speaking Engagement April 30, 2025Diagnosing the Disease: Regulation of LDTs and IVDsBen Wolf will present during this virtual program hosted by the Practicing Law Institute (PLI).
-
Press Release July 9, 2024Alston & Bird Adds Three Lateral Partners to Bolster Corporate, Health Care, and Real Estate Practices from New Offices in Chicago and Century CityAlston & Bird has strengthened its Corporate, Health Care, and Real Estate practices with the addition of three new partners. Dave Zampa, who focuses on complex M&A transactions, health care, and life sciences, and Erin Felchner, who concentrates on real estate finance, will join the firm’s new Chicago office. In addition, Brielle Cuskelly, who handles real estate and real estate finance matters, will reside in the firm’s new Century City office.Press Release July 9, 2024Alston & Bird Adds Three Lateral Partners to Bolster Corporate, Health Care, and Real Estate Practices from New Offices in Chicago and Century CityAlston & Bird has strengthened its Corporate, Health Care, and Real Estate practices with the addition of three new partners. Dave Zampa, who focuses on complex M&A transactions, health care, and life sciences, and Erin Felchner, who concentrates on real estate finance, will join the firm’s new Chicago office. In addition, Brielle Cuskelly, who handles real estate and real estate finance matters, will reside in the firm’s new Century City office.
-
In the News January-February 2023Quality Assurance Magazine | Three Food Industry Trend Predictions for the Year AheadAngela Spivey is quoted on 2023’s top regulation trends in the food industry and offers insights for companies looking to prepare, and Sam Jockel weighs in on his and Ben Wolf’s predictions.In the News January-February 2023Quality Assurance Magazine | Three Food Industry Trend Predictions for the Year AheadAngela Spivey is quoted on 2023’s top regulation trends in the food industry and offers insights for companies looking to prepare, and Sam Jockel weighs in on his and Ben Wolf’s predictions.
-
In the News December 2022Wilkes University | The Roads Less Traveled: Two Distinguished Alums Follow Different Paths to SuccessAnthony Fanucci is profiled on how his pharmaceutical degree led him to a career in health care law and is quoted.In the News December 2022Wilkes University | The Roads Less Traveled: Two Distinguished Alums Follow Different Paths to SuccessAnthony Fanucci is profiled on how his pharmaceutical degree led him to a career in health care law and is quoted.
-
In the News May 4, 2022Inside Health Policy, FDA Week | Woodcock to Chair FDA’s Cannabis Council as It Implements Data PlanMarc Scheineson is quoted on the Food and Drug Administration’s expected approach to regulating CBD.In the News May 4, 2022Inside Health Policy, FDA Week | Woodcock to Chair FDA’s Cannabis Council as It Implements Data PlanMarc Scheineson is quoted on the Food and Drug Administration’s expected approach to regulating CBD.
-
In the News February 17, 2022Medtech Insight | Still Mulling EUA Transition Options? Don’t Wait too Long, Attorney SaysBen Wolf is quoted on practical considerations for manufacturers in light of the Food and Drug Administration’s post-pandemic medical device transition plan.In the News February 17, 2022Medtech Insight | Still Mulling EUA Transition Options? Don’t Wait too Long, Attorney SaysBen Wolf is quoted on practical considerations for manufacturers in light of the Food and Drug Administration’s post-pandemic medical device transition plan.
-
In the News February 2, 2022The Hill | Lobbying WorldAlix Marzelli is mentioned as a new health care counsel in the firm’s Washington, D.C. office.In the News February 2, 2022The Hill | Lobbying WorldAlix Marzelli is mentioned as a new health care counsel in the firm’s Washington, D.C. office.
-
In the News January 31, 2022Bloomberg Law | Wake Up CallAlix Marzelli is noted as a new health care counsel in the firm’s Washington, D.C. office.In the News January 31, 2022Bloomberg Law | Wake Up CallAlix Marzelli is noted as a new health care counsel in the firm’s Washington, D.C. office.
-
In the News January 28, 2022Law360 | Alston & Bird Nabs Former FDA Associate Chief CounselAlix Marzelli is featured as a new health care counsel in the firm’s Washington, D.C. office and Cathy Burgess and Marc Scheineson are quoted on her joining.In the News January 28, 2022Law360 | Alston & Bird Nabs Former FDA Associate Chief CounselAlix Marzelli is featured as a new health care counsel in the firm’s Washington, D.C. office and Cathy Burgess and Marc Scheineson are quoted on her joining.
-
General Publications January 14, 2022“Practical Considerations for Draft Transition Plans for Devices Under EUAs or COVID Enforcement Policies,” Medical Device and Diagnostic Industry, January 14, 2022.On Jan. 31, 2020, the Department of Health and Human Services declared a public health emergency (PHE) related to the global COVID-19 pandemic. The declaration of a PHE enabled the FDA to issue a declaration regarding the appropriateness of utilizing emergency use authorizations. This article discusses what medical device manufacturers should know about the FDA’s transition measures for devices under COVID-19 EUAs.General Publications January 14, 2022“Practical Considerations for Draft Transition Plans for Devices Under EUAs or COVID Enforcement Policies,” Medical Device and Diagnostic Industry, January 14, 2022.On Jan. 31, 2020, the Department of Health and Human Services declared a public health emergency (PHE) related to the global COVID-19 pandemic. The declaration of a PHE enabled the FDA to issue a declaration regarding the appropriateness of utilizing emergency use authorizations. This article discusses what medical device manufacturers should know about the FDA’s transition measures for devices under COVID-19 EUAs.
Highlights
Alston & Bird Adds Three Lateral Partners to Bolster Corporate, Health Care, and Real Estate Practices from New Offices in Chicago and Century City
Alston & Bird has strengthened its Corporate, Health Care, and Real Estate practices with the addition of three new partners. Dave Zampa, who focuses on complex M&A transactions, health care, and life sciences, and Erin Felchner, who concentrates on real estate finance, will join the firm’s new Chicago office. In addition, Brielle Cuskelly, who handles real estate and real estate finance matters, will reside in the firm’s new Century City office.